Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 10/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 10/20 | 0.57 |
| ▸ | TAS1R2 | Q8TE23 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SPR | P35270 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18608551 | 0.94 | PDE2A (0.55) | TAS1R3TAS1R1TAS1R2ALDH1A1HSD17B10 | |
| SCHEMBL18608344 | 0.82 | BRD4 (0.47) | TAS1R3TAS1R1TAS1R2ALDH1A1HSD17B10 | |
| SCHEMBL18608352 | 0.81 | LMNA (0.55) | TAS1R3TAS1R1TAS1R2ALDH1A1HSD17B10 | |
| SCHEMBL18608560 | 0.80 | MTNR1A (0.47) | ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL9132837 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL9130840 | 0.79 | ALDH1A1 (0.49) | ALDH1A1HSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL9130815 | 0.79 | ALDH1A1 (0.49) | ALDH1A1HSD17B10KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9129366 | 0.79 | ALDH1A1 (0.49) | ALDH1A1HSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL18608648 | 0.77 | LIPG (0.50) | ALDH1A1 | |
| SCHEMBL18608253 | 0.75 | ALDH1A1 (0.62) | TAS1R3TAS1R1TAS1R2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190112316-A1 | THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | LYSOSOMAL THERAPEUTICS INC (US) | 2019-04-18 | — | — | US | disclosed |
| WO-2017040879-A1 | THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112316-A1 | THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | PARK7, GAA, TYMP | TAS1R3 953/4885TAS1R1 926/4885TAS1R2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.